19 Oct: Exubera bong gets Pfired

Pfizer CEO Jeff Kindler has finally thrown out the Exubera baby with the bong water, saying, “We made an important decision regarding Exubera, a product for which we initially had high expectations. Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted.” Exubera is the first inhalable insulin diabetes drug to market but was later pulled from the market because of poor sales due to doctors concerns about its long-term safety. A video at PharmaGossip sums it up:

05 Sep: Exubera: inhaler or rolling pin?

Although Exubera is turning out to be a flop, you can’t say it’s not good for something. Turns out it’s good for disciplining deadbeat husbands, fighting off dogs while jogging, and rolling dough. According to analysts, Pfizer was slow to market with Exubera, initially assigning it to a sales team that was not prepared to explain it to doctors, and then not beginning to advertise it until this summer. Some doctors complain the Exubera inhaler costs too much and isn’t covered by many insurers. It also looks like something you would find in a college frat house. Pfizer vice chairman David Shedlarz responded to this uproar by saying, “Exubera was not our finest day. We made a lot of mistakes…